A5036238582- Diabetes Treatment and Management
- Diabetes Management and Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Medication Adherence and Compliance
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic and Hepatic Oncology Research
- Chronic Kidney Disease and Diabetes
- Pancreatitis Pathology and Treatment
- Hepatitis B Virus Studies
- Metabolism, Diabetes, and Cancer
- Inflammatory Bowel Disease
- Hepatitis Viruses Studies and Epidemiology
- Liver Disease Diagnosis and Treatment
- Heart Failure Treatment and Management
- Pancreatic function and diabetes
- Diabetic Foot Ulcer Assessment and Management
- Pharmaceutical Practices and Patient Outcomes
- Neuroendocrine Tumor Research Advances
- Dialysis and Renal Disease Management
- Diabetes Management and Education
- Urinary Tract Infections Management
- HIV Research and Treatment
- Pharmacology and Obesity Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Renal Diseases and Glomerulopathies
Boehringer Ingelheim (United States)
2017-2023
Boehringer Ingelheim (Sweden)
2022
Boehringer Ingelheim (Germany)
2018-2021
Brigham and Women's Hospital
2018-2021
Merck & Co., Inc., Rahway, NJ, USA (United States)
2003-2019
Harvard University
2018-2019
Merck (Japan)
2015
Boehringer Ingelheim (Taiwan)
2015
United States Military Academy
2001-2014
Johns Hopkins University
2005
Before licensure of varicella vaccine in 1995, was a universal childhood disease the United States, causing 4 million cases, 11,000 hospitalizations, and 100 deaths every year.To examine population-based surveillance data 3 communities to document impact vaccination program.Active for conducted among populations Antelope Valley, Calif; Travis County, Tex; West Philadelphia, Pa; from January 1, December 31, 2000. Reporting sites included child care centers, schools, universities, physicians,...
Reports of multiple sclerosis developing after hepatitis B vaccination have led to the concern that this vaccine might be a cause in previously healthy subjects.
The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces the risk of hospitalization for heart failure (HHF) by 35%, on top standard care patients with type mellitus (T2D) and established cardiovascular disease. EMPRISE Comparative Effectiveness Safety) study aims to assess empagliflozin's effectiveness, safety, healthcare utilization routine from August...
A lipodystrophic syndrome and metabolic abnormalities have been observed in HIV-infected patients treated with highly active antiretroviral therapy (HAART). murine model of lipodystrophy is associated decreased levels adiponectin, an adipocyte-secreted protein, the administration which improves these mice. To investigate association adiponectin changes human lipodystrophy, we conducted a cross-sectional study 112 HAART. Mean were higher no fat redistribution (FR) vs. FR (4.8 +/- 5.0 2.2 2.7...
To assess the impact of hypoglycemia on clinical outcomes among hospitalized, insulin-treated patients.In a retrospective study, hospitalizations in 2005-2007 were identified from US inpatient electronic medical records database. All encounters for patients with valid blood glucose measurement included, except those length stay <24 hours or >30 days. In an encounter-based analysis, associations between hypoglycemic (glucose ≤70 mg/dL) severe ≤50 episodes and mortality, ischemic events,...
Progressive decline in renal function has been well described patients with Type 2 diabetes mellitus, but few studies have assessed the risk of acute failure a large population diabetes. This study quantified associated General Practice Research Database from UK.Patients (n = 119,966) and without 1,794,516) were identified Database. Patients end-stage disease excluded. Crude incidence multivariate-adjusted hazard ratios estimated for relative to those Cox regression models adjusted variety...
To evaluate the risk of urinary tract infections (UTI) in subjects with newly diagnosed type 2 diabetes mellitus (T2DM). Subjects aged ≥ 18 years and T2DM between 1/1/10 12/31/10 were identified using MarketScan® databases, which are representative commercially insured US population those both Medicare supplemental coverage. The index date was first diagnosis 2010 (date randomly selected for without T2DM). matched (1:1) by date, age, gender, urban/rural location, region. All had continuous...
Aim To evaluate the extent to which balance in unmeasured characteristics of patients with type 2 diabetes (T2DM) was achieved claims data, by comparing against more detailed information from linked electronic health records (EHR) data. Methods Within a large US commercial insurance database and using cohort design, we identified T2DM initiating linagliptin or comparator agent within class (ie, another dipeptidyl peptidase‐4 inhibitor) outside pioglitazone sulphonylurea) between May 2011...
Type 2 diabetes is a reported risk factor for more frequent and severe urinary tract infections (UTI). We sought to quantify the annual healthcare cost burden of UTI in type diabetic patients.Adult patients diagnosed with were identified MarketScan administrative claims data. occurrence costs assessed during 1-year period. examined UTI-related visit antibiotic among UTI, comparing those versus without history previous year (prevalent vs. incident cases). estimated total incremental by...
Significance Statement Information about the type of health care costs associated with CKD across all stages in a general population substantial comorbidity burden is lacking. Using electronic medical records an integrated delivery system, authors evaluated patients CKD, or without diabetes mellitus, cardiovascular disease, and heart failure, by eGFR level. Despite high use currently available therapies, inpatient were increasing proportion total each higher category, regardless presence...
BackgroundComorbidities may differently affect treatment response and cause-specific outcomes in heart failure (HF) with preserved (HFpEF) vs. mid-range/mildly-reduced (HFmrEF) reduced (HFrEF) ejection fraction (EF), complicating trial design. In patients HF, we performed a comprehensive analysis of type 2 diabetes (T2DM), atrial fibrillation (AF) chronic kidney disease (CKD), outcomes.Methods resultsOf 42,583 from the Swedish HF registry (23% HFpEF, 21% HFmrEF, 56% HFrEF), 24% had T2DM, 51%...
Abstract Aim To investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin versus dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment across the broad spectrum of cardiovascular risk. Methods In a population‐based cohort study we identified 39 072 pairs 1:1 propensity score‐matched adult T2D or DPP‐4 inhibitors, using data from US commercial insurance databases Medicare between August 2014 September 2017. The primary were composite...
To identify the characteristics associated with glycemic response to newly initiated insulin therapy.We identified 1,139 type 2 diabetic patients who therapy between 1 January 2009 and 30 June 2010. Outcomes of interest were proportion achieving A1C <7% mean change in within 3-9 months.Mean at initiation was 8.2 vs. 9.2% among those did not attain (P < 0.001). Within a 5 months, 464 (40.7%) attained <7%. In multivariable analyses controlling for regimen, dose, oral agent use, preinsulin...
Aim To examine the impact of diabetes duration, chronic pancreatitis and other factors on pancreatic cancer risk. Methods This retrospective cohort study using UK General Practice Research Database compared incidence risk in patients with type 2 mellitus ( T2DM ) versus without diabetes. Multivariate Cox regression adjusting for age, sex, history pancreatitis, gallbladder disease, obesity, smoking alcohol use Charlson comorbidity index was used to estimate hazard ratio HR [95% confidence...
To quantify willingness-to-pay (WTP) for reducing pill burden and dosing frequency among patients with type 2 diabetes mellitus (T2DM), to examine the effect of on likely medication adherence.Participants were US adults T2DM oral antihyperglycemic therapy. Each patient completed an online discrete-choice experiment (DCE) eight choice questions, each including a pair hypothetical profiles. profile was defined by reduction in average glucose (AG), daily dosing, chance mild-to-moderate stomach...
Abstract Aim To evaluate the effectiveness of empagliflozin in clinical practice East Asia Empagliflozin Comparative Effectiveness and Safety (EMPRISE) study. Materials methods Data were obtained from Medical Vision database (Japan), National Health Insurance Service (South Korea) (Taiwan). Patients aged ≥ 18 years with type 2 diabetes initiating or a dipeptidyl peptidase‐4 (DPP‐4) inhibitor 1:1 propensity score (PS) matched into sequentially built cohorts new users naïve to both drug...
Abstract Hepatocellular carcinoma is one of the leading causes cancer death worldwide. The etiology liver multifactorial, and infection with hepatitis B virus (HBV), whose pathogenesis exacerbated by acquisition mutations that accelerate carcinogenesis, or C (HCV) dietary exposure to aflatoxin B1 all contribute elevating one's risk for this disease. In study, we sought determine contributions these agents measuring occurrence an HBV 1762T/1764A double mutation, aflatoxin-specific 249G→T...
Previous research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, well-recognized challenge in type 2 diabetes mellitus (T2DM). The objective of this study was to elicit preferences for alternative regimens oral antihyperglycemic therapies patients with T2DM quantify differences different characteristics.Preferences drugs (OAD) were evaluated by surveying the United States (US). Survey participants adult US who taking no or only 1 OAD...
Aim: To estimate the rate of adherence to oral antihyperglycemic monotherapy for patients with type 2 diabetes in US and describe factors associated these patients. Materials methods: In this retrospective cohort analysis, aged 18 years or older a diagnosis received between 1 January 2007 31 March 2010 were identified using large US-based health care claims database. The index date was defined as first prescription during period. Patients had have continuous enrollment database 12 months...
Studies of progression kidney dysfunction typically focus on renal replacement therapy or percentage decline in estimated glomerular filtration rate (eGFR) as outcomes. Our aim was to compare real-world patients with and without T2D estimate from clinically defined categories disease all-cause mortality.This an observational cohort study 31,931 33,201 age/sex matched type 2 diabetes (T2D) who had a serum creatinine urine albumin-to-creatinine ratio (UACR) dipstick proteinuria (DP) values. We...